Back to Search
Start Over
The Effect of Delay in Care among Patients Requiring Intravitreal Injections
- Source :
- Ophthalmology Retina. 5:975-980
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Purpose To examine the effect of delay in care on visual acuity (VA) in patients requiring intravitreal injections (IVIs). Design Retrospective cohort study. Participants Patients 18 years of age or older with diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), or both; neovascular age-related macular degeneration (nAMD); or retinal vein occlusion (RVO) scheduled to see a retina specialist during the mandated lockdown period (March 14 - May 4, 2020 [the coronavirus disease 2019 period]) and who had received an IVI in the 12 weeks prior. Methods Chart review was performed and demographics, diagnoses, procedures, and VA were recorded. Main Outcome Measures VA in patients who completed, canceled, and no-showed for the scheduled visit. Results Of the 1041 total patients, 620 (60%) completed the scheduled visit, whereas 376 (36%) canceled and 45 (4%) no-showed. In patients who missed the visit, the average delay in care was 5.34 weeks. In those who missed a visit, VA was assessed at the subsequent visit. Patients who canceled a visit were older, and patients who no-showed had lower baseline vision (mean Early Treatment Diabetic Retinopathy Study letters ± standard error [SE]: no-show, 53.27 ± 3.21 letters; canceled, 60.79 ± 1.11 letters; and completed, 62.81 ± 0.84 letters; P = 0.0101) and were more likely to have DME, PDR, or both (no-show, 13 patients [29%]; canceled, 56 patients [16%]; completed, 81 patients [13%]; P = 0.0456). Patients who missed a visit lost vision as compared with the patients who completed one (no-show, –5.024 ± 1.88 letters; canceled, –1.633 ± 0.65 letters; completed, 0.373 ± 0.50 letters; P = 0.0028). Patients with DME, PDR, or both (–3.48 ± 1.95 letters vs. 2.71 ± 1.75 letters; P = 0.0203), with RVO (–3.22 ± 1.41 letters vs. 0.95 ± 1.23 letters; P = 0.0230), and, to lesser degree, with nAMD (–1.23 ± 0.70 letters vs. –0.24 ± 0.56 letters; P = 0.2679) lost vision compared with patients with same diagnoses who completed the scheduled visit. Conclusions In patients requiring IVIs, a delay in care of 5.34 weeks resulted in vision loss. It was seen in all patients, but was more prominent in patients with DME, PDR or both and RVO. Further studies are necessary to examine whether these vision changes persist over a longer duration.
- Subjects :
- Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Time Factors
Visual acuity
genetic structures
Visual Acuity
Angiogenesis Inhibitors
Comorbidity
Macular Edema
Time-to-Treatment
03 medical and health sciences
0302 clinical medicine
Ranibizumab
Ophthalmology
Internal medicine
Occlusion
medicine
Humans
Macula Lutea
Macular edema
Aged
Ohio
Retrospective Studies
030304 developmental biology
Aged, 80 and over
0303 health sciences
Diabetic Retinopathy
SARS-CoV-2
business.industry
COVID-19
Retrospective cohort study
Diabetic retinopathy
Middle Aged
Macular degeneration
medicine.disease
eye diseases
Intravitreal Injections
030221 ophthalmology & optometry
Female
medicine.symptom
business
Tomography, Optical Coherence
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 24686530
- Volume :
- 5
- Database :
- OpenAIRE
- Journal :
- Ophthalmology Retina
- Accession number :
- edsair.doi.dedup.....340b055e3ecb4d81164c6fa6c914057e
- Full Text :
- https://doi.org/10.1016/j.oret.2020.12.020